IL202828A0 - 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids - Google Patents

6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids

Info

Publication number
IL202828A0
IL202828A0 IL202828A IL20282809A IL202828A0 IL 202828 A0 IL202828 A0 IL 202828A0 IL 202828 A IL202828 A IL 202828A IL 20282809 A IL20282809 A IL 20282809A IL 202828 A0 IL202828 A0 IL 202828A0
Authority
IL
Israel
Prior art keywords
pyrrolopyridinyl
pyrimidin
aids
cancer
treatment
Prior art date
Application number
IL202828A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL202828A0 publication Critical patent/IL202828A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL202828A 2007-06-21 2009-12-17 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids IL202828A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028515A DE102007028515A1 (de) 2007-06-21 2007-06-21 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
PCT/EP2008/004151 WO2008155000A1 (de) 2007-06-21 2008-05-23 6-(pyrrolopyridinyl)- pyrimidin-2-yl-amin-derivate und ihre verwendung zur behandlung von krebs und aids

Publications (1)

Publication Number Publication Date
IL202828A0 true IL202828A0 (en) 2010-06-30

Family

ID=39916277

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202828A IL202828A0 (en) 2007-06-21 2009-12-17 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids

Country Status (16)

Country Link
US (1) US8546390B2 (enExample)
EP (1) EP2155745B1 (enExample)
JP (1) JP5411849B2 (enExample)
KR (1) KR20100040862A (enExample)
CN (1) CN101679425B (enExample)
AR (1) AR067081A1 (enExample)
AU (1) AU2008266584B2 (enExample)
BR (1) BRPI0812944A2 (enExample)
CA (1) CA2691223C (enExample)
DE (1) DE102007028515A1 (enExample)
EA (1) EA016160B1 (enExample)
ES (1) ES2533873T3 (enExample)
IL (1) IL202828A0 (enExample)
MX (1) MX2009013341A (enExample)
WO (1) WO2008155000A1 (enExample)
ZA (1) ZA201000432B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524858A (ja) * 2007-04-10 2010-07-22 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 縮合環複素環キナーゼ調節因子
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
MX2015009270A (es) * 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
PT2970265T (pt) * 2013-03-15 2018-10-23 Plexxikon Inc Compostos heterocíclicos e suas utilizações
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
US11129808B2 (en) 2016-03-15 2021-09-28 University Of South Florida PKC-delta-I inhibitor formulations and uses thereof
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
CA3079029A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases
BR112021019957A2 (pt) * 2019-04-09 2021-12-07 Plexxikon Inc Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma
EP3993787A4 (en) 2019-08-06 2023-07-12 Recurium IP Holdings, LLC Estrogen receptor modulators for treating mutants
CN118772140A (zh) * 2023-04-07 2024-10-15 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
KR101216372B1 (ko) * 2004-03-30 2013-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌
EP1773807A2 (en) * 2004-06-14 2007-04-18 Takeda San Diego, Inc. Kinase inhibitors
EP1781654A1 (en) * 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP4954086B2 (ja) * 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー １ｈ−ピロロ［２，３−ｂ］ピリジン
ATE469151T1 (de) 2005-05-16 2010-06-15 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Also Published As

Publication number Publication date
AU2008266584A1 (en) 2008-12-24
BRPI0812944A2 (pt) 2014-12-16
EA016160B1 (ru) 2012-02-28
US8546390B2 (en) 2013-10-01
JP5411849B2 (ja) 2014-02-12
WO2008155000A1 (de) 2008-12-24
JP2010530376A (ja) 2010-09-09
CA2691223C (en) 2015-12-01
KR20100040862A (ko) 2010-04-21
MX2009013341A (es) 2010-01-18
AU2008266584B2 (en) 2013-04-04
DE102007028515A1 (de) 2008-12-24
CN101679425A (zh) 2010-03-24
EP2155745A1 (de) 2010-02-24
AR067081A1 (es) 2009-09-30
US20110082140A1 (en) 2011-04-07
EP2155745B1 (de) 2015-01-28
CN101679425B (zh) 2013-11-06
ZA201000432B (en) 2010-10-27
CA2691223A1 (en) 2008-12-24
EA201000004A1 (ru) 2010-06-30
ES2533873T3 (es) 2015-04-15

Similar Documents

Publication Publication Date Title
IL202828A0 (en) 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
AP2960A (en) Substituted pyrimidines for the treatment of diseases such as cancer
ZA201202384B (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
IL216283A0 (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
ZA201000106B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA201000087B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
IL206189A (en) Compounds for use in cancer treatment
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
IL226363A0 (en) Compounds and methods for treating cancer
GB0517387D0 (en) Combinations for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
IL205339A0 (en) Compounds and methods for the treatment of cancer
ZA200810524B (en) Pyrimidine derivatives useful in the treatment of cancer
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0517386D0 (en) Combinations for the treatment of cancer
HK1170238A (en) Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
HK1166787A (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer